RxDoctor Payments Data

Critt Aardema, MD

Family Medicine · Roy, UTNPI 1891003265

Payments from drug & device makers

$9,827in general payments, 2019–2025

Across 607 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$846
  • Astellas Pharma US Inc$774
  • Boehringer Ingelheim$720
  • Johnson & Johnson$525
  • Pfizer$455
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$9,51597%
  • Education$3123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,827 in reported general payments places this provider in the 90th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$165,098
Medicare patients
249
Services billed
4,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$110,282
JardianceEmpagliflozin69$73,497
EliquisApixaban58$61,090
MounjaroTirzepatide32$42,955
XareltoRivaroxaban28$39,112
JanuviaSitagliptin Phosphate33$38,345
MyrbetriqMirabegron40$34,838
TrulicityDulaglutide27$31,361
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,450
Janumet XrSitagliptin Phos/Metformin Hcl15$12,811
SymbicortBudesonide/Formoterol Fumarate16$7,742
BelsomraSuvorexant12$5,419
Omeprazole278$5,142
VyvanseLisdexamfetamine Dimesylate11$4,821
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$248$110,28274 claims
Lilly USA, LLCMounjaro, Trulicity$846$74,31559 claims
Boehringer IngelheimJardiance$720$73,49769 claims
PfizerEliquis$455$61,09058 claims
MerckJanuvia, Janumet Xr, Belsomra$136$56,57560 claims
Johnson & JohnsonXarelto$525$39,11228 claims
Astellas Pharma US IncMyrbetriq$774$34,83840 claims
GSKTrelegy Ellipta$297$15,45020 claims
AstraZenecaSymbicort$316$7,74216 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$227$4,82111 claims
AbbVieSynthroid$1,895$2,01224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 928 family medicine providers in Utah.

Other family medicine in Roy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →